Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwan Bezard

Showing results (161-170 of 298) with videos related to

Pageof 30
Sort By:
Synapse (New York, N.Y.)|October 24, 2009
Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primateMonty A Silverdale, Christopher Kobylecki, Penelope J Hallett, et al.
BMC Bioinformatics|October 28, 2006
Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGEKim Kultima, Birger Scholz, Henrik Alm, et al.
Neurobiology of Disease|June 9, 2009
High frequency stimulation of the entopeduncular nucleus sets the cortico-basal ganglia network to a new functional state in the dystonic hamsterRené Reese, Giselle Charron, Agnès Nadjar, et al.
Journal of Neuropathology and Experimental Neurology|June 19, 2009
The nigrostriatal pathway in Creutzfeldt-Jakob diseaseAnne Vital, Pierre-Olivier Fernagut, Marie-Hélène Canron, et al.
Neurobiology of Aging|April 9, 2008
IGF-1 signaling reduces neuro-inflammatory response and sensitivity of neurons to MPTPAgnès Nadjar, Olivier Berton, Shuhong Guo, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 11, 2014
Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's diseaseWai Kin D Ko, Elsa Pioli, Qin Li, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 26, 2003
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmosetMichael P Hill, Erwan Bezard, Steven G McGuire, et al.
Experimental Neurology|July 29, 2009
Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate modelQuentin Barraud, Virginie Lambrecq, Claude Forni, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 2, 2016
Targeting α-synuclein: Therapeutic optionsBenjamin Dehay, Mickael Decressac, Mathieu Bourdenx, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 24, 2023
GRK2-Targeted Knockdown as Therapy for Multiple System AtrophyMiguel Lopez-Cuina, Paul Guérin, Nathalie Dutheil, et al.
Pageof 30

Showing results (161-170 of 298) with videos related to

Sort By:
Pageof 30
Synapse (New York, N.Y.)|October 24, 2009
Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primateMonty A Silverdale, Christopher Kobylecki, Penelope J Hallett, et al.
BMC Bioinformatics|October 28, 2006
Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGEKim Kultima, Birger Scholz, Henrik Alm, et al.
Neurobiology of Disease|June 9, 2009
High frequency stimulation of the entopeduncular nucleus sets the cortico-basal ganglia network to a new functional state in the dystonic hamsterRené Reese, Giselle Charron, Agnès Nadjar, et al.
Journal of Neuropathology and Experimental Neurology|June 19, 2009
The nigrostriatal pathway in Creutzfeldt-Jakob diseaseAnne Vital, Pierre-Olivier Fernagut, Marie-Hélène Canron, et al.
Neurobiology of Aging|April 9, 2008
IGF-1 signaling reduces neuro-inflammatory response and sensitivity of neurons to MPTPAgnès Nadjar, Olivier Berton, Shuhong Guo, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 11, 2014
Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's diseaseWai Kin D Ko, Elsa Pioli, Qin Li, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 26, 2003
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmosetMichael P Hill, Erwan Bezard, Steven G McGuire, et al.
Experimental Neurology|July 29, 2009
Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate modelQuentin Barraud, Virginie Lambrecq, Claude Forni, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 2, 2016
Targeting α-synuclein: Therapeutic optionsBenjamin Dehay, Mickael Decressac, Mathieu Bourdenx, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 24, 2023
GRK2-Targeted Knockdown as Therapy for Multiple System AtrophyMiguel Lopez-Cuina, Paul Guérin, Nathalie Dutheil, et al.
Pageof 30